RenaissThera is a pharmaceutical company dedicated to developing affordable, novel small-molecule targeted therapies leveraging AI platforms. Our goal is to innovate for underserved populations and bridge the gaps in novel therapy access worldwide. We focus on high-unmet-need areas of prevalent diseases in cardio-metabolic therapy including diabetes type 2 and obesity. Leveraging our Innovation Platform powered by GenAI tools, we identify small-molecule therapies for proven pathways, ensuring cutting-edge solutions for patients. With a leadership team and scientific advisory board boasting extensive experience in global pharmaceutical product development, RenaissThera is committed to bringing innovative treatments to those in need around the world.
Mentions in press and media 3
| Date | Title | Description |
| 12.12.2024 | RenaissThera: Pioneering AI-Driven Solutions for Cardio-Metabolic Diseases | In the bustling tech hub of Bengaluru, India, a new player is emerging in the biotechnology arena. RenaissThera has successfully closed its seed funding round, marking a significant milestone in its mission to combat cardio-metabolic diseas... |
| 10.12.2024 | RenaissThera Closes Seed Funding Round | RenaissThera, a Bengaluru, India-based biotechnology company for cardio-metabolic diseases, raised an undisclosed amount in Seed funding. Backers included undisclosed angel investors. The company intends to use the funds to accelerate the d... |
| 10.12.2024 | RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases | Bengaluru, Karnataka, India RenaissThera Private Limited (“RenaissThera”), a pioneering Bengaluru-based biotechnology company, has successfully closed its seed funding round backed by angel investors. This funding will accelerate the develo... |